Research programme: anti-CD19 CAR transduced T cells - Beijing Doing Biomedical

Drug Profile

Research programme: anti-CD19 CAR transduced T cells - Beijing Doing Biomedical

Alternative Names: Anti-CD19 CAR T cells - Beijing Doing Biomedical; CD19 CAR redirected autologous T-cells - Beijing Doing Biomedical; CD19 chimeric antigen receptor T-cells - Beijing Doing Biomedical; CD19 targeted CAR T cells - Beijing Doing Biomedical

Latest Information Update: 04 Feb 2016

Price : $50

At a glance

  • Originator Beijing Doing Biomedical
  • Class Antineoplastics; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action CD19 antigen modulators; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 04 Feb 2016 Beijing Doing Biomedical plans a phase I trial for Haematological malignancies (Second-line therapy or greater) in China (Parenteral) (NCT02656147)
  • 09 Sep 2015 Beijing Doing Biomedical plans a phase I trial for Haematological malignancies (CD19+, Refractory metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT02546739)
  • 01 Jan 2015 Preclinical trials in Acute lymphoblastic leukaemia in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top